The Health Care Select Sector SPDR® Fund Newsroom

Merck's male HPV vaccine has been approved domestically for the first time. Industry insiders believe this will promote the future approval of domestic products under development.

① Gardasil has become the first and currently the only approved HPV vaccine for men in China. ② Industry experts believe that the approval of the new indication is a new exploration in terms of pharmacological principles and other aspects. ③ Currently, companies such as Kang Li Wei Shi and Beijing Wantai Biological Pharmacy Enterprise have made arrangements in this field.

cls.cn38minutes ago

Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today

Benzinga18:15 ET

Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today

Kevin Travers16:22 ET

Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies

Seeking Alpha14:58 ET

Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst

Benzinga14:45 ET

Psychiatric Hospital Operator Acadia Healthcare Earns Upgrade Amid Expected Recovery In 2025

Benzinga14:14 ET

These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe

Seeking Alpha14:09 ET

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Benzinga14:06 ET

Unpacking the Latest Options Trading Trends in Merck & Co

Benzinga14:00 ET

FDA Issues Draft Guidance on Developing Weight Loss Drugs

Seeking Alpha11:53 ET

Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not

Seeking Alpha11:17 ET

Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns

Seeking Alpha11:12 ET

Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock

Kevin TraversJan 7 10:46 ET

Eli Lilly's Options: A Look at What the Big Money Is Thinking

BenzingaJan 7 09:45 ET

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT NewswiresJan 7 09:08 ET

Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...

BenzingaJan 7 08:16 ET

Bird Flu Claims First U.S. Life in Louisiana

Seeking AlphaJan 6 17:22 ET

Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today

Kevin TraversJan 6 16:22 ET

Danaher Analyst Ratings

BenzingaJan 6 16:10 ET · Ratings

AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06

BenzingaJan 6 16:05 ET